CLINICAL TRIALS

Hope for patients in need

ZielBio is developing novel therapeutics to treat several forms of cancer and other serious diseases to meaningfully improve patients’ lives. We conduct clinical trials to evaluate the efficacy of our promising therapies in patients with cancer who may benefit from them. Our clinicians follow strict scientific standards to protect patients.
An older man smiles and swings his baby granddaughter in his arms

Currently enrolling: ZB131 Phase 1/2 clinical trial

ZielBio is currently recruiting people with certain types of advanced or metastatic cancers for the expansion stage of our Phase 1/2 trial evaluating our novel, investigational therapy, ZB131. Researchers are studying the safety of ZB131 and its ability to help people with solid tumors.

ClinicalTrials.gov Identifier: NCT05074472
An older man smiles and swings his baby granddaughter in his arms
An older man smiles and swings his baby granddaughter in his arms

About the ZB131 clinical trial

What is ZB131?

ZB131 is a monoclonal antibody that binds to cancer cells with cancer-specific plectin (CSP) on their surface, inducing a form of programmed cell death. For more information about monoclonal antibody treatments for cancer, click here.

Are you eligible?

This study is for people who meet the following eligibility criteria:

  • Have advanced or metastatic pancreatic, ovarian, or bile duct cancer
  • Are 18 years of age or older
  • Have failed all available therapies or are ineligible for standard of care treatment

Your doctor or healthcare provider can help determine if you may be a good fit for the ZB131 clinical trial. For a complete list of eligibility criteria, see ClinicalTrials.gov.

What to expect
  • Potential participants will start with a screening visit to confirm their eligibility for the study. The staff at the trial site will take patients’ medical history and perform a physical exam to ensure they meet the study requirements.
  • ZB131 will be administered via IV every week at one of our trial sites.
  • During study visits, participants will undergo tests and procedures in addition to those that are part of regular care for their type of cancer to study the treatment’s effect.

Trial sites

The following sites are currently recruiting participants for the ZB131 trial. If after speaking with your healthcare provider, you believe you may be a good fit for the ZB131 trial, please contact the site most convenient to you for more information.
Location
Site Name
Contact
Status
Phoenix,
Arizona, 85054
Mayo Clinic – Phoenix
Clinical Trials Referral Office |
855-776-0015
Recruiting
Mayo Clinic – Phoenix
Phoenix, Arizona, 85054
Clinical Trials Referral Office |
855-776-0015
Recruiting
Jacksonville,
Florida, 32224
Mayo Clinic – Jacksonville
Clinical Trials Referral Office |
855-776-0015
Recruiting
Mayo Clinic – Jacksonville
Jacksonville, Florida, 32224
Clinical Trials Referral Office |
855-776-0015
Recruiting
Rochester,
Minnesota, 55905
Mayo Clinic – Rochester
Clinical Trials Referral Office |
855-776-0015
Recruiting
Mayo Clinic – Rochester
Rochester, Minnesota, 55905
Clinical Trials Referral Office |
855-776-0015
Recruiting
Nashville,
Tennessee, 37203
Sarah Cannon Research Institute
Sarah Cannon |
asksarah@sarahcannon.com
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Sarah Cannon |
asksarah@sarahcannon.com
Recruiting
Austin,
Texas, 78758
NEXT Oncology
Cynthia DeLeon |
210-580-9521 |
cdeleon@nextoncology.com
Recruiting
NEXT Oncology
Austin, Texas, 78758
Cynthia DeLeon |
210-580-9521 |
cdeleon@nextoncology.com
Recruiting
Houston,
Texas, 77030
MD Anderson Cancer Center
Rabia Khan |
713-563-4667 |
RKhan@mdanderson.org
Recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Rabia Khan |
713-563-4667 |
RKhan@mdanderson.org
Recruiting
San Antonio,
Texas, 78229
NEXT Oncology
Cynthia DeLeon |
210-580-9521 |
cdeleon@nextoncology.com
Recruiting
NEXT Oncology
San Antonio, Texas, 78229
Cynthia DeLeon |
210-580-9521 |
cdeleon@nextoncology.com
Recruiting
Charlottesville,
Virginia, 22908
University of Virginia
Ralph Watson |
uvacancertrials@hscmail.mcc.virginia.edu
Recruiting
University of Virginia
Charlottesville, Virginia, 22908
Ralph Watson |
uvacancertrials@hscmail.mcc.virginia.edu
Recruiting
Fairfax,
Virginia, 22031
NEXT Oncology
Frances Gatlin |
210-580-9500 |
fgatlin@nextoncology.com
Recruiting
NEXT Oncology
Fairfax, Virginia, 22031
Frances Gatlin |
210-580-9500 |
fgatlin@nextoncology.com
Recruiting

FAQs

How do I join this trial?

Your doctor or a healthcare provider can help you determine if you are eligible for this trial. You can also email clinical@zielbio.com or the contact for the site most convenient to you for more information.

Am I guaranteed to receive ZB131 in this trial?

Yes. All participants will receive ZB131 as part of this study.

Do I need to travel to participate in the study?

Yes. You will have to visit one of our study sites weekly for IV infusions of ZB131.

Is there a cost to participating in this clinical trial?

The study drug ZB131 will be provided to you at no cost. ZielBio will also cover all associated exams and reasonable travel costs. You will not receive other compensation for participation.

After enrolling in the clinical trial, can I withdraw if I choose to?

Yes. Taking part in this clinical trial is voluntary and entirely up to you.

Do you have an expanded use policy?

At this time, ZielBio is unable to provide ZB131 to patients outside the study.